Cardiometabolic issues have become a global epidemic, presenting an urgent public health challenge. A group of risk factors contributing to cardiometabolic diseases have been identified in recent decades, among which the modifiable factors account for a critical portion of the attributable risk fraction. However, there is still an amount of unrecognized residual risk, leading to the high global incidence of cardiometabolic disease. Given the important role of lipid metabolism in cardiometabolic health, accumulating evidence has suggested the potential application of lipid-related markers in the prevention and intervention of cardiometabolic diseases. These markers include but are not limited to remnant cholesterol, lipoprotein(a) and triglyceride-glucose index, which capture the biological characteristics of atherogenicity, inflammation, insulin resistance and other unknown aspects. Understanding the relationship between these lipid-related markers and cardiometabolic diseases is crucial for comprehensive risk stratification and intervention strategies that go beyond the current health management pattern focused on lipid metabolism. Numerous questions and potential clinical applications associated with lipid markers necessitate a thorough exploration, especially from a population-level perspective.
This Research Topic aims to comprehensively evaluate the residual risk of cardiometabolic diseases related to lipid-related markers, including but not limited to remnant cholesterol, lipoprotein(a), and triglyceride-glucose index, and to evaluate the risk reclassification capacity for the precise prevention and potential intervention strategy to promote cardiometabolic health from the population level.
We welcome Original Research and Reviews on the relationship between lipid-related markers and the occurrence and prognosis of cardiometabolic and chronic diseases. We are particularly interested in manuscripts on the role of remnant cholesterol and lipoprotein(a), as well as the effects of the triglyceride-glucose index and its modified forms as they relate to cardiometabolic and aging-related diseases. Analyses focusing on risk reclassification and prediction models based on these lipid-related markers are also highly valued.
A deeper understanding of the distinct roles and risk classification capacity of residual lipid markers will improve the clinical application and promote the prevention and management of cardiometabolic diseases from the aspect of lipid metabolism health. The specific research sub-topics include but are not limited to:
• Remnant cholesterol and disease prevention and prognosis
• Risk re-stratification capacity of remnant and composite lipid markers
• Current and future prevention and intervention strategies for remnant lipids.
Keywords:
cardiometabolic health, residual risk, lipid marker, risk restratification
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Cardiometabolic issues have become a global epidemic, presenting an urgent public health challenge. A group of risk factors contributing to cardiometabolic diseases have been identified in recent decades, among which the modifiable factors account for a critical portion of the attributable risk fraction. However, there is still an amount of unrecognized residual risk, leading to the high global incidence of cardiometabolic disease. Given the important role of lipid metabolism in cardiometabolic health, accumulating evidence has suggested the potential application of lipid-related markers in the prevention and intervention of cardiometabolic diseases. These markers include but are not limited to remnant cholesterol, lipoprotein(a) and triglyceride-glucose index, which capture the biological characteristics of atherogenicity, inflammation, insulin resistance and other unknown aspects. Understanding the relationship between these lipid-related markers and cardiometabolic diseases is crucial for comprehensive risk stratification and intervention strategies that go beyond the current health management pattern focused on lipid metabolism. Numerous questions and potential clinical applications associated with lipid markers necessitate a thorough exploration, especially from a population-level perspective.
This Research Topic aims to comprehensively evaluate the residual risk of cardiometabolic diseases related to lipid-related markers, including but not limited to remnant cholesterol, lipoprotein(a), and triglyceride-glucose index, and to evaluate the risk reclassification capacity for the precise prevention and potential intervention strategy to promote cardiometabolic health from the population level.
We welcome Original Research and Reviews on the relationship between lipid-related markers and the occurrence and prognosis of cardiometabolic and chronic diseases. We are particularly interested in manuscripts on the role of remnant cholesterol and lipoprotein(a), as well as the effects of the triglyceride-glucose index and its modified forms as they relate to cardiometabolic and aging-related diseases. Analyses focusing on risk reclassification and prediction models based on these lipid-related markers are also highly valued.
A deeper understanding of the distinct roles and risk classification capacity of residual lipid markers will improve the clinical application and promote the prevention and management of cardiometabolic diseases from the aspect of lipid metabolism health. The specific research sub-topics include but are not limited to:
• Remnant cholesterol and disease prevention and prognosis
• Risk re-stratification capacity of remnant and composite lipid markers
• Current and future prevention and intervention strategies for remnant lipids.
Keywords:
cardiometabolic health, residual risk, lipid marker, risk restratification
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.